CTOs on the Move

Metacrine

www.metacrine.com

 
We are a clinical-stage biopharmaceutical company focused on discovering and developing best-in-class therapies for patients with liver and gastrointestinal, or GI, diseases. Since our founding in 2014, we have invested in building a foundation of chemistry and biology expertise to drive innovative drug discovery and development. We believe these internal capabilities allow us to gain insights into disease targets and mechanisms and more quickly and purposefully design therapies with characteristics that we view as key to safety and efficacy. With this systematic approach, we have designed novel, proprietary farnesoid X receptor (FXR) clinical product candidates arising from a unique chemical ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.metacrine.com
  • 3985 Sorrento Valley Boulevard Suite C
    San Diego, CA USA 92121
  • Phone: 858.369.7800

Executives

Name Title Contact Details

Funding

Metacrine raised $36M on 08/05/2015
Metacrine raised $65M on 06/05/2018

Similar Companies

NOVOS

NOVOS develops science-based solutions to slow down human aging. NOVOS is a Public Benefit Corporation devoted to improving human longevity & health.

Eyetech Pharmaceuticals

Eyetech Pharmaceuticals, Inc. is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Farkas IRM

Farkas IRM is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rani Therapeutics

Rani Therapeutics has developed the RaniPill™, a platform technology for the oral delivery of biologic drugs. Millions of patients with chronic conditions require biologic drugs that today can only be injected. These injections are painful and inconvenient and often affect both patient compliance and quality of life. The pharma industry has been searching for decades to convert injectables into pills, and we believe the solution is the RaniPill™ capsule. We have demonstrated bioavailability similar to subcutaneous injections in both preclinical and clinical studies. Rani has an internal pipeline of molecules, and active collaborations with Novartis and Takeda. The research and technology behind Rani Therapeutics came out of InCube Labs, a multi-disciplinary life sciences R&D lab focused on breakthrough medical innovations. InCube is led by Mir Imran, a prolific medical inventor, entrepreneur, and investor.

Ignyta

Ignyta, located in San Diego, California, is a biotechnology company developing precision medicine with integrated Rx/Dx solutions for cancer patients. Its goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells for the customized treatment of cancer patients. The company's present focus is on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases